Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Advanced Cancer 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Ranitidine × Clear all
NCT02999633 2022-03-21

ISLAY

Sanofi

Phase 2 Terminated
14 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01287520 2019-02-25

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
41 enrolled 28 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡